Quintiles Transnational Corp. has launched the expansion of its strategic partnering group under the NovaQuest brand to further NovaQuest's alliance with TPG-Axon Capital, a global investment firm with more than $5.8 billion in equity capital. NovaQuest helps life-science companies realize greater value from their product portfolios through strategic partnering solutions.
Through its alliance with TPG-Axon, NovaQuest has access to capital to fund strategic partnerships of virtually any size. TPG-Axon already has committed several hundred millions of dollars to NovaQuest partnerships to date.
NovaQuest has invested approximately $1.5 billion over the last five years on various drug projects with both major pharmaceutical companies and smaller biotech firms. Within NovaQuest are Quintiles' key investment partnering functions, including agreement structuring and due diligence (formerly known as PharmaBio Development) and alliance management.
"NovaQuest's launch and its alliance with TPG-Axon is confirmation of the power of partnering with Quintiles," said Quintiles Transnational founder, chairman and chief executive officer, Dennis Gillings, Ph.D., CBE. "Customers can tap into our global development and commercialization infrastructure, deal-making expertise, and financial Resources to create tailor-made solutions to their most significant strategic and financial challenges."
NovaQuest offers partnering solutions in three major categories: Co development and co-promotion investments in which NovaQuest invests with cash or Quintiles services, or a combination of both, in a customer's drug development or commercialization programs. TPG-Axon will be NovaQuest's partner for investments of this type.